Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

British Journal of Cancer

Volumn 111, Issue 9, 2014, Pages 1750-1756

  Schwab, C L ^a   Bellone, S ^a   English, D P ^a   Roque, D M ^a   Lopez, S ^b   Cocco, E ^a   Nicoletti, R ^a   Bortolomai, I ^c   Bonazzoli, E ^a   Ratner, E ^a   Silasi, D A ^a   Azodi, M ^a   Schwartz, P E ^a   Rutherford, T J ^a   Santin, A D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

afatinib; chemoresistance; endometrial cancer; HER2 Neu; tyrosine kinase inhibitors; uterine serous cancer

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR S6; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MIDDLE AGED; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UTERINE SEROUS CARCINOMA; AGED; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; DRUG EFFECTS; DRUG SCREENING; ENDOMETRIAL NEOPLASMS; ENZYME IMMUNOASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL CULTURE; UTERINE NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; IN VITRO TECHNIQUES; MICE; MICE, SCID; MIDDLE AGED; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908607011     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.519     Document Type: Article

References (33)

1. Acharya S, Hensley ML, Montag AC, Fleming GF (2005) Rare uterine cancers. Lancet Oncol 6(12): 961-971.
2. BerchuckA,Kamel A, Whitaker R,Kerns B,OltG, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC Jr. (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50(13): 4087-4091.
3. Black JD, English DP, Roque DM, Santin AD (2014) Targeted therapy in uterine serous carcinoma: An aggressive variant of endometrial cancer. Womens Health 10(1): 45-57.
4. Buza N, English DP, Santin AD, Hui P (2013) Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 26(12): 1605-1612.
5. Cohen RB (2014) Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-And ErbB family-Targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev 40(4): 567-577.
6. Dungo RT, Keating GM (2013) Afatinib: First global approval. Drugs 73(13): 1503-1515.
7. Engelsen IB, Stefansson IM, Beroukhim R, SellersWR,MeyersonM, Akslen LA, Salvesen HB (2008) HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 32(2): 307-316.
8. English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD (2013) Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol 209(5): 465 e1-465 e9.
9. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV (2010) Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecolo Oncol 116(1): 15-20.
10. Goff BA (2005) Uterine papillary serous carcinoma: What have we learned over the past quarter century?. Gynecol Oncol 98(3): 341-343.
11. Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer E (2009) Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res 69(Suppl 3): 5060.
12. HamiltonCA, CheungMK,Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94(5): 642-646.
13. Hartman Z, Zhao H, Agazie YM (2013) HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signalling. Oncogene 32(35): 4169-4180.
14. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC (1992) HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 47(2): 179-185.
15. Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS (2013) Monitoring afatinib treatment in HER2-positive gastric cancer with 18FFDG and 89Zr-Trastuzumab PET. J Nucl Med 54(6): 936-943.
16. Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavanagh JJ, Wharton JT (1992) Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 46(3): 317-321.
17. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34): 4702-4711.
18. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T (2012) A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 133(3): 1057-1065.
19. Mitri Z, Constantine T, O'Regan R (2012) The HER2 receptor in breast cancer: Pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012: 743193.
20. Modjtahedi H, Cho BC, Michel MC, Solca F (2014) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol 387(6): 505-521.
21. Nicklin JL, Copeland LJ (1996) Endometrial papillary serous carcinoma: Patterns of spread and treatment. Clin Obstet Gynecol 39(3): 686-695.
22. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, ZakowskiMF, Politi KA, PaoW (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Inves 119(10): 3000-3010.
23. Reungwetwattana T, Dy GK (2013) Targeted therapies in development for non-small cell lung cancer. J Carcinog 12: 22.
24. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP (2002) Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8(5): 1271-1279.
25. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005) Amplification of c-erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma. Cancer 104(7): 1391-1397.
26. Schwartz PE (2006) The management of serous papillary uterine cancer. Curr Opin Oncol 18(5): 494-499.
27. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27): 3327-3334.
28. Solca F, Adolf GR, Jones H, Uttenreuther-Fischer MM (2010) Beyond trastuzumab: Second-generation targeted therapies for HER2-positive breast cancer. Drugs for HER-2-positive Breast Cancer, Milestones in Drug Therapy, Sibilia M, Zielinski CC, Bartsch R, Grunt TW pp 91-107. Springer Science, Business Media LLC: New York, Philadelphia.
29. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W (2012) HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2(10): 922-933.
30. Talwar S, Cohen S (2012) Her-2 targeting in uterine papillary serous carcinoma. Gynecol Oncol Case Rep 2(3): 94-96.
31. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16(2): 273-278.
32. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH (1989) Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49(8): 2087-2090.
33. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD (2013) Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci USA 110(8): 2916-2921.